NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
49 hedge funds and large institutions have $6.65M invested in NeuBase Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
81% less call options, than puts
Call options by funds: $44K | Put options by funds: $233K
Holders
49
Holding in Top 10
–
Calls
$44K
Puts
$233K
Top Buyers
| 1 | +$3.05M | |
| 2 | +$222K | |
| 3 | +$104K | |
| 4 |
TSS
Two Sigma Securities
New York
|
+$66.6K |
| 5 |
Renaissance Technologies
New York
|
+$43.3K |
Top Sellers
| 1 | -$369K | |
| 2 | -$75K | |
| 3 | -$58.1K | |
| 4 |
GBA
Garrison Bradford & Associates
New York
|
-$25.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.6K |